Funnily I think all this actually helps Thyrocare. For one, all this mess is happening because Pharmeasy’s investors really like Thyrocare and don’t want to lose it. Second, with Manipal investing in Pharmeasy, it’s going to get a near-controlling stake in the company. Eventually Thyrocare could be integrated into the Manipal ecosystem. All of Manipal’s patients could potentially be doing their tests through Thyrocare, so access to a larger market.
| Subscribe To Our Free Newsletter |
